CASE REPORTS
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Ocular surface reconstruction with keratolimbal allograft for the treatment of severe or recurrent symblepharon.

Cornea 2015 June
PURPOSE: To describe an ocular surface reconstruction technique using keratolimbal allograft (KLAL) tissue to repair and treat severe or recurrent symblepharon.

METHODS: Five eyes of 5 patients (age 23-71 years) with severe or recurrent symblepharon causing symptomatic restrictive diplopia in primary gaze have been treated. After meticulous symblepharon lysis and scar tissue removal, KLAL tissue was sutured onto the ocular surface and used as a spacer to prevent recurrent scar formation. Patients have been followed from 12 to 28 months.

RESULTS: All eyes have been free of symblepharon recurrence in areas reconstructed with KLAL tissues. Mild recurrences of adhesions have occurred in areas posterior to the KLAL graft and none have recurred over the KLAL segments. Primary gaze diplopia has been resolved in all cases with only mild residual diplopia in extreme lateral gazes for 3 patients.

CONCLUSIONS: Ocular surface reconstruction with KLAL tissue effectively achieves functional and anatomic success in fornix repair for patients with severe or recurrent symblepharon. Donor KLAL is a robust tissue alternative to traditional amniotic membrane or conjunctival autografts.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app